Agostina Siniscalchi
Overview
Explore the profile of Agostina Siniscalchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
459
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
More S, Federici I, Bossi A, Rupoli S, Morsia E, Manieri V, et al.
Hemasphere
. 2025 Jan;
9(1):e70079.
PMID: 39850649
No abstract available.
2.
Vergori A, Matusali G, Cimini E, Bordi L, Borrelli P, Lanini S, et al.
Vaccines (Basel)
. 2024 Jul;
12(7).
PMID: 39066422
. We aimed to report the real-world use and outcomes over time in immunocompromised individuals receiving tixagevimab/cilgavimab (T/C) pre-exposure prophylaxis (PrEP). . This observational study included participants who received T/C...
3.
Vergori A, Lepri A, Chiuchiarelli M, Mazzotta V, Metafuni E, Matusali G, et al.
Int J Infect Dis
. 2024 Apr;
144:107042.
PMID: 38614231
Objectives: Whether pre-exposure prophylaxis (PrEP) with tixagevimab/cilgavimab 150 mg/150 mg (T/C) in individuals with hematologic disease (HD) may lead to a reduced risk of SARS-CoV-2 breakthrough infection (BTI)/hospitalization, or death...
4.
Fazio F, Franceschini L, Tomarchio V, Rago A, Garzia M, Cupelli L, et al.
EJHaem
. 2022 Jul;
3(1):121-128.
PMID: 35846211
The multiple myeloma (MM) treatment has changed over the last years due to the introduction of novel drugs. Despite improvements in the MM outcome, MM remains an incurable disease. Daratumumab...
5.
Rago A, Siniscalchi A, Tordi A, Andrizzi C, Campagna S, di Toritto T
Tumori
. 2021 Feb;
107(6):NP37-NP40.
PMID: 33525991
Background: Multiple myeloma is a plasma cell dyscrasia accounting for 1% of neoplastic diseases and is the second most common hematologic malignancy after lymphoma. Pulmonary arterial hypertension is characterized by...
6.
Rago A, Tordi A, Siniscalchi A, Andrizzi C, Campagna S, di Toritto T
Blood Res
. 2020 Sep;
55(3):187-189.
PMID: 32989179
No abstract available.
7.
Gentile M, Specchia G, Derudas D, Galli M, Botta C, Rocco S, et al.
Haematologica
. 2020 Feb;
106(1):291-294.
PMID: 32107338
No abstract available.
8.
Mina R, Bonello F, Petrucci M, Liberati A, Conticello C, Ballanti S, et al.
Haematologica
. 2020 Feb;
106(4):1079-1085.
PMID: 32107329
Despite remarkable advances in the treatment of multiple myeloma in the last decades, the prognosis of patients harboring high-risk cytogenetic abnormalities remains dismal as compared to that of standard-risk patients....
9.
DAgostino M, De Paoli L, Conticello C, Offidani M, Ria R, Petrucci M, et al.
Crit Rev Oncol Hematol
. 2018 Nov;
132:9-16.
PMID: 30447931
Background: Risk-adapted therapy is a common strategy in curable hematologic malignancies: standard-risk patients receive less intensive treatment, whereas high-risk patients require a more intensive approach. This model cannot be applied...
10.
Abruzzese E, Trawinska M, Neri B, Bondanini F, Fratoni S, Tendas A, et al.
Acta Haematol
. 2018 Nov;
140(4):231-233.
PMID: 30384359
No abstract available.